This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
MMSI Stock Declines Despite Q1 Earnings Beating Estimates, Margins Up
by Zacks Equity Research
Merit Medical benefits from revenue growth in both segments and the majority of its product categories within its Cardiovascular unit in the first quarter of 2025.
Here's What Key Metrics Tell Us About Encompass Health (EHC) Q1 Earnings
by Zacks Equity Research
Although the revenue and EPS for Encompass Health (EHC) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Encompass Health (EHC) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Encompass Health (EHC) delivered earnings and revenue surprises of 15.13% and 1.31%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Amedisys (AMED) Tops Q1 Earnings Estimates
by Zacks Equity Research
Amedisys (AMED) delivered earnings and revenue surprises of 10.62% and 0%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Are Medical Stocks Lagging Encompass Health (EHC) This Year?
by Zacks Equity Research
Here is how Encompass Health (EHC) and Heron Therapeutics (HRTX) have performed compared to their sector so far this year.
Why Encompass Health (EHC) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Unlocking Q1 Potential of Encompass Health (EHC): Exploring Wall Street Estimates for Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Encompass Health (EHC), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2025.
Here's Why Encompass Health (EHC) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks Industry Outlook Highlights DaVita, Encompass Health, Option Care Health and Addus HomeCare
by Zacks Equity Research
DaVita, Encompass Health, Option Care Health and Addus HomeCare have been highlighted in this Industry Outlook article.